06 May Kidney-on-a-Chip Technology Allows For Faster Drug Safety Analysis
MedicalResearch.com Interview with:
Shuichi Takayama, PhD
Professor, Department of Biomedical Engineering & Macromolecular Science and Engineering
Associate Director, Michigan Center for Integrative Research in Critical Care
Director, Microfluidics in Biomedical Sciences Training Program
University of Michigan
MedicalResearch.com: What is the background for this study? What are the main findings?
Dr. Takayama: In this particular study, we tested a once a day vs continuous administration of drug and showed once daily administration is better. The type of study was something that could not be done well in animals because drug clearance is much faster than humans. And existing human clinical data has been inconclusive for this particular drug and is too expensive to collect new data specifically for this drug.
MedicalResearch.com: What should readers take away from your report?
Dr. Takayama: Miniature human surrogate model that provides better understanding of how to more safely administer drugs.
MedicalResearch.com: What recommendations do you have for future research as a result of this study?
Dr. Takayama: The results highlight the importance of studying drug administration timing/dynamics in addition to the more common static drug concentration level studies. The paper provides a template for study of other drugs and organ models.
MedicalResearch.com: Is there anything else you would like to add?
Dr. Takayama: Professor Se Joong Kim is a nephrologist and he was key in driving this research.
MedicalResearch.com: Thank you for your contribution to the MedicalResearch.com community.
Shuichi Takayama et al. Pharmacokinetic profile that reduces nephrotoxicity of gentamicin in a perfused kidney-on-a-chip. Biofabrication, March 2016
Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.
Last Updated on May 6, 2016 by Marie Benz MD FAAD